Edition:
United States

Ibio Inc (IBIO.A)

IBIO.A on American Stock Exchange

0.19USD
17 Jan 2018
Change (% chg)

$0.00 (+0.43%)
Prev Close
$0.19
Open
$0.18
Day's High
$0.21
Day's Low
$0.18
Volume
285,851
Avg. Vol
115,070
52-wk High
$0.56
52-wk Low
$0.14

Chart for

About

iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformati... (more)
No analyst recommendations are available for .

Overall

Beta: 0.64
Market Cap(Mil.): $21.35
Shares Outstanding(Mil.): 115.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 33.55 16.42
EPS (TTM): -- -- --
ROI: -- 15.06 33.31
ROE: -- 16.59 17.56

BRIEF-Ibio Inc Prices $4.50 Mln Firm Commitment Offering Of Common Stock

* IBIO, INC. PRICES $4,500,000 FIRM COMMITMENT OFFERING OF COMMON STOCK

Nov 29 2017

BRIEF-Ibio Announces Proposed Public Offering Of Common Stock

* IBIO, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

Nov 28 2017

BRIEF-IBio Inc ‍initiated litigation against Fraunhofer-Gesellschaft

* IBio Inc - ‍initiated litigation against Fraunhofer-Gesellschaft regarding iBio's technology and intellectual property​ Source text for Eikon: Further company coverage:

Nov 06 2017

BRIEF-AETHLON MEDICAL ANNOUNCES PRODUCTION COLLABORATION WITH IBIO INC

* AETHLON MEDICAL ANNOUNCES LARGE-SCALE PRODUCTION COLLABORATION

Oct 16 2017

BRIEF-IBIO ANNOUNCES MANUFACTURING COLLABORATION WITH AETHLON MEDICAL

* IBIO ANNOUNCES MANUFACTURING COLLABORATION WITH AETHLON MEDICAL

Oct 16 2017

BRIEF-iBio CDMO LLC partners with TheoremDx Inc to develop proteins for rapid diagnostic testing products

* iBio Inc - co with its unit iBio CDMO LLC, has partnered with TheoremDx Inc to develop proteins for rapid diagnostic testing products Source text for Eikon: Further company coverage:

Sep 18 2017

BRIEF-Ibio enters into common stock purchase agreement for up to $16 mln with Lincoln Park Capital

* Ibio Inc enters into common stock purchase agreement for up to $16.0 million with Lincoln Park Capital

Jul 24 2017

Competitors

  Price Chg
Vical Incorporated (VICL.OQ) $1.84 0.00
Novavax, Inc. (NVAX.OQ) $1.73 +0.08
Medicago Inc. (MDG.TO) -- --
Novartis AG (NOVN.S) CHF83.24 -0.32
GlaxoSmithKline plc (GSK.L) 1,359.20 +4.20
CSL Limited (CSL.AX) $142.68 +0.66
AstraZeneca plc (AZN.L) 4,990.50 -58.50
Merck Ltd (MERK.NS) Rs1,534.55 --

Earnings vs. Estimates